Arcus Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	117	112	383	78	15	8.35	1.41	0
Revenue Growth (YoY)	4.46%	-70.76%	391.03%	420.00%	79.58%	491.15%	-	-
Gross Profit	117	112	383	78	15	8.35	1.41	0
Selling, General & Admin	117	104	72	43	25.23	13.57	7.64	3.94
Research & Development	340	288	257	159	78.48	49.65	47.22	14.25
Operating Expenses	457	392	329	202	103.71	63.21	54.85	18.18
Operating Income	-340	-280	54	-124	-88.71	-54.86	-53.44	-18.18
Interest Expense / Income	0	0	0	0	0	0	-0.78	-0.21
Other Expense / Income	-39	-14	-1	-1	-4	-5.27	0.42	-
Pretax Income	-301	-266	55	-123	-84.71	-49.59	-53.08	-17.97
Income Tax	6	1	2	0	0	0	0	0
Net Income	-307	-267	53	-123	-84.71	-49.59	-53.08	-17.97
Shares Outstanding (Basic)	74	72	69	55	44	35	2	1
Shares Outstanding (Diluted)	74	72	74	55	44	35	2	1
Shares Change	2.78%	-2.70%	35.04%	25.04%	26.60%	1793.51%	111.61%	-
EPS (Basic)	-4.15	-3.71	0.76	-2.24	-1.93	-1.43	-29.03	-20.80
EPS (Diluted)	-4.15	-3.71	0.71	-2.24	-1.93	-1.43	-29.03	-20.80
Free Cash Flow	-330	432	-282	108	-75.39	-46.74	-30.57	-17.04
Free Cash Flow Per Share	-4.46	6.00	-4.07	1.97	-1.72	-1.35	-16.72	-19.73
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-290.60%	-250.00%	14.10%	-158.97%	-591.39%	-656.76%	-3782.09%	-
Profit Margin	-262.39%	-238.39%	13.84%	-157.69%	-564.73%	-593.73%	-3756.69%	-
Free Cash Flow Margin	-282.05%	385.71%	-73.63%	138.46%	-502.58%	-559.55%	-2163.69%	-
Effective Tax Rate	-	-	3.64%	-	-	-	-	-
EBITDA	-285	-252	62	-119	-81.13	-45.93	-51.25	-16.87
EBITDA Margin	-243.59%	-225.00%	16.19%	-152.56%	-540.88%	-549.86%	-3626.68%	-
Depreciation & Amortization	16	14	7	4	3.58	3.66	2.61	1.31
EBIT	-301	-266	55	-123	-84.71	-49.59	-53.86	-18.18
EBIT Margin	-257.26%	-237.50%	14.36%	-157.69%	-564.73%	-593.73%	-3811.54%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).